3 Reasons to Buy Teva Pharmaceuticals

Teva (TEVA) faces a big hurdle once Copaxone loses patent protection, but only if Mylan (MYL) and Novartis (NVS) win FDA approval for their biosimilars. Here are three reasons investors should consider owning Teva.

May 19, 2014 at 6:30PM

When it comes to keeping big pharma executives up at night, no one is better than Teva Pharmaceuticals (NYSE:TEVA). Teva is a giant in generic drugs with a product portfolio that includes more than 850 compounds combining to generate more than $20 billion in annual sales.

But it hasn't been all smooth sailing for Teva shareholders. Over the past two years, worries that competitors Mylan (NASDAQ:MYL) and Novartis' Sandoz (NYSE:NVS) will launch generic biosimilars of Teva's $4 billion-a-year multiple sclerosis drug Copaxone have taken shares on a roller coaster ride.

Given the threat of Copaxone biosimilars is looming, it may be tempting to sell Teva shares, but here are three good reasons for investors to buy them instead.

TEVA Chart

TEVA data by YCharts.

1. The generic threat to Copaxone may prove overstated
There's no question Copaxone's patent will expire, but there's considerable question as to whether biosimilars from Mylan and Novartis, which is teamed up with Momenta, will win FDA approval. And there are even more questions about how much market share those biosimilars can eventually capture from Teva if they do get the go-ahead.

That's because Copaxone isn't as easily duplicated as traditional small-molecule drugs. Copaxone is a hybrid biologic, which means it's a complex structure manufactured in living cell cultures. That means it's virtually impossible to make an exact copy, and it also means Mylan and Novartis are faced with unique challenges in proving the comparability of their biosimilars to the FDA.

Even if regulators do eventually give the nod to Mylan and Novartis, approval may not be granted on day one of Copaxone's patent expiration.

If approval is delayed, it will not only mean more money for Teva shareholders in terms of sales, but more time for Teva to convert patients to its new Copaxone formulation.

That new formulation won FDA approval just a few months ago, and the company is already working hard to reach out to patients. During the company's January presentation at JPMorgan's health care conference, it estimated it could conservatively switch 45% of Copaxone users to the longer-lasting version, which can be taken just three times weekly, rather than daily. If Teva can execute on that conversion goal, the threat of biosimilars could become more muted.

2. Patent expiration supports growth through 2015
$28 billion in branded drug patents lost exclusivity in 2013, but that number climbs to $34 billion this year, and a whopping $66 billion in 2015. The opportunity to sell more generics should drive plenty of profit-friendly tailwinds for Teva given the pace of patent expiration is picking up rather than slowing down. 

3. Biosimilars offer a potential path for future growth
While the outlook for branded patent expiration is good news, even better news may be upcoming patent expiration for biologics.

Spending on specialty drugs like biologics increased 14% last year and is expected to grow more than 17% per year over the next three years, according to Express Scripts.

That growth is coming in part because biologics are helping people live longer. As a result, cancer patients, for example, are taking more drugs for longer periods. Spending growth is also being caused by biologics' higher prices, which can be substantially more than prior-generation small-molecule drugs.

So, why is this good news for Teva? While Teva hasn't jumped into biosimilars like Mylan and Novartis, its sheer size and experience with Copaxone gives it plenty of potential to make a splash into the developing market once the biosimilar pathway to approval becomes clearer.

Industry R&D is actively developing a significant number of new biologics that will eventually lose patent protection, and when they do, that pricing should provide biosimilar manufacturers much healthier margins than they've historically received for generic small-molecule drugs. Currently, prices for biosimilars are roughly 60% to 70% of the branded drug price, versus just 20%-30% for small-molecule generics. Of course, there are additional R&D expenses involved in developing biosimilars, so that additional spending is likely a portion of the price difference.

Fool-worthy final thoughts
Investors will undoubtedly worry over Copaxone if Mylan and Novartis win the FDA green light, but that worry may be overblown, at least for now. Teva has had years to build up a loyal following of Copaxone patients, and many of these patients will welcome the idea of fewer weekly injections offered by Teva's new Copaxone variation.

Additionally, investors can take solace knowing that the generic patent schedule is working in Teva's favor. That means there should be plenty of revenue generating new launches in the coming year. Even better, Teva's cost cutting has the company expecting its margin on generic drugs could improve by 10% to 15%. And Teva investors should also benefit long term from the introduction of high margin biosimilars. Given those three factors, the outlook for Teva may not be as bleak as previously feared.

Teva's not the only dividend stock to consider -- here are the top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers